National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 25 of 41
Antiviral Therapy and HIV in the Female Genital Tract
NCT00067106
Long-term Follow-up of HIV Infected Patients Identified During Early Infection
NCT00086372
Dressing Preparations for Smallpox
NCT00063856
Prevention of GBS Colonization Via Immunity
NCT00128219
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
NCT00065390
Anthrax-rPA: Safety, Tolerability, Immunogenicity
NCT00063843
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00042289
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
NCT00063817
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
NCT00062621
Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
NCT00090194
Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
NCT00095329
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
NCT00078195
Analysis of Immune Responses to HIV Vaccines
NCT00068978
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
NCT00055120
Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease
NCT00056355
Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics
NCT00057499
Immune Responses to Smallpox Vaccination
NCT00325975
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
NCT00006441
Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox
NCT00053742
HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
NCT00056758
Screening HIV-Infected Patients for Vaccine Studies
NCT00051519
Safety of RG2077 in Patients With Multiple Sclerosis
NCT00076934
Alternative Dosing Strategy for Anti-HIV Drugs
NCT00059384
Cause and Natural Course of Pediatric-Onset Mastocytosis
NCT00050193
Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease
NCT00048789
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
NCT00050856
HIV-1 Vaccine Test in Uninfected Adult Volunteers
NCT00047931
Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
NCT00048347
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
NCT00047918
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
NCT00052182
Growth Hormone to Increase Immune Function in People With HIV
NCT00071240
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
NCT00050505
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
NCT00068146
Phase I Trial of Smallpox Vaccine
NCT00046397
Promoting Adherence to Anti-HIV Drug Regimens
NCT00051805
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
NCT00039741
HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
NCT00043641
ICC-1132 - Candidate Vaccine Against P Falciparum Malaria
NCT00587249
Valganciclovir in Congenital CMV Infants
NCT00031434
Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali
NCT00341783
Antibody Production in Immune Disorders
NCT00023504
Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor
NCT00041769
Daclizumab to Treat Wegener's Granulomatosis
NCT00040248
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
NCT00038987
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
NCT00017719
Treatment With hOKT3gamma1(Ala-Ala) in T1DM
NCT00806572
Posaconazole to Treat Invasive Fungal Infections
NCT00033982
Leprosy Skin Test Antigens Trial
NCT00128193
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
NCT00028314
Treatment of Hepatitis C in Hemophilic Patients With HIV
NCT00055341
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.